Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.

Biotechnology

Abcuro

Alex Martin

Stephanie Amador

Eileen Brennan

Weilee Chen

Zarna Patel

Andrew Marth

Jeff Geary

Jeffrey Luk

Karma Tashi

Chidi Obi

Bill Yates

Daniel Mansuri

Kristin Lurk

Ricky Motschwiller

Raquel Orozco

Donna Byrne

Terry Chaney

Mike Gress

Karen Tubridy

Garry Weems

Hugo Lemessurier

Dave Borbas

Janaki Subramanyam

Dulce Soler-Ferran

LaDonna Hoffer

H. Jeffrey Wilkins, MD

The Leadership Team at Abcuro is responsible for strategic direction and oversight of the company's clinical development initiatives, particularly focusing on innovative therapies for autoimmune diseases and cancer. This team, comprising experts in research, clinical science, and regulatory affairs, collaborates to drive the advancement of ABC008 and ensure compliance with regulatory standards while fostering interdisciplinary communication to facilitate successful clinical trials. Their leadership is crucial in navigating the complex landscape of biotechnology and ensuring the company meets its scientific and therapeutic goals.

Leadership Team

Management and Directors

Quality and Regulatory Team

Leadership Team

About

Team members

Other teams at Abcuro

Management and Directors

Quality and Regulatory Team